Capricor (CAPR) Rises 2.5% Pre-Market Following August FDA Developments

CAPR Capricor Therapeutics Inc

$6.13 +4.25%

View chart & analysis →

GDDY +6.02% HIMS -0.27% WIX +4.84% CLBT +2.52% UWMC +3.60% 3 more

1. 1Capricor Therapeutics (CAPR) rose 2.5% in pre-market trading to $10.16
2. 2In mid-August, the FDA indicated its intent to review the amended BLA for deramiocel for the preservation of upper limb function in Duchenne muscular dystrophy
3. 3No direct catalyst filing confirmed; shares await review following August FDA updates and Cantor Fitzgerald upgrade

Source InvestorsHub +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →